Shield Therapeutics plc (LON:STX) Insider Anders Lundstrom Acquires 575,000 Shares

Shield Therapeutics plc (LON:STX) insider Anders Lundstrom purchased 575,000 shares of the stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of GBX 4 ($0.05) per share, for a total transaction of £23,000 ($28,905.37).

Shield Therapeutics Stock Performance

Shares of STX stock opened at GBX 3.80 ($0.05) on Friday. Shield Therapeutics plc has a 52-week low of GBX 1.06 ($0.01) and a 52-week high of GBX 5.95 ($0.07). The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50. The stock has a market cap of £37.50 million, a PE ratio of -0.98 and a beta of 1.42. The business has a 50-day simple moving average of GBX 2.76 and a 200-day simple moving average of GBX 3.37.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.